Cisplatin/carboplatin cross-resistance in ovarian cancer.

Forty-six patients who were treated with cisplatin or carboplatin for ovarian cancer developed resistant disease (no change in measurable disease or progressive disease) and 'crossed over' to the other platinum compound. Three patients (6.5%) responded to this second treatment but these pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gore, M. E., Fryatt, I., Wiltshaw, E., Dawson, T., Robinson, B. A., Calvert, A. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247292/
https://www.ncbi.nlm.nih.gov/pubmed/2803953
_version_ 1782150950745538560
author Gore, M. E.
Fryatt, I.
Wiltshaw, E.
Dawson, T.
Robinson, B. A.
Calvert, A. H.
author_facet Gore, M. E.
Fryatt, I.
Wiltshaw, E.
Dawson, T.
Robinson, B. A.
Calvert, A. H.
author_sort Gore, M. E.
collection PubMed
description Forty-six patients who were treated with cisplatin or carboplatin for ovarian cancer developed resistant disease (no change in measurable disease or progressive disease) and 'crossed over' to the other platinum compound. Three patients (6.5%) responded to this second treatment but these patients had no survival advantage compared to the non-responders. One responder had progressive disease on cisplatin before crossing over to carboplatin.
format Text
id pubmed-2247292
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22472922009-09-10 Cisplatin/carboplatin cross-resistance in ovarian cancer. Gore, M. E. Fryatt, I. Wiltshaw, E. Dawson, T. Robinson, B. A. Calvert, A. H. Br J Cancer Research Article Forty-six patients who were treated with cisplatin or carboplatin for ovarian cancer developed resistant disease (no change in measurable disease or progressive disease) and 'crossed over' to the other platinum compound. Three patients (6.5%) responded to this second treatment but these patients had no survival advantage compared to the non-responders. One responder had progressive disease on cisplatin before crossing over to carboplatin. Nature Publishing Group 1989-11 /pmc/articles/PMC2247292/ /pubmed/2803953 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Gore, M. E.
Fryatt, I.
Wiltshaw, E.
Dawson, T.
Robinson, B. A.
Calvert, A. H.
Cisplatin/carboplatin cross-resistance in ovarian cancer.
title Cisplatin/carboplatin cross-resistance in ovarian cancer.
title_full Cisplatin/carboplatin cross-resistance in ovarian cancer.
title_fullStr Cisplatin/carboplatin cross-resistance in ovarian cancer.
title_full_unstemmed Cisplatin/carboplatin cross-resistance in ovarian cancer.
title_short Cisplatin/carboplatin cross-resistance in ovarian cancer.
title_sort cisplatin/carboplatin cross-resistance in ovarian cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247292/
https://www.ncbi.nlm.nih.gov/pubmed/2803953
work_keys_str_mv AT goreme cisplatincarboplatincrossresistanceinovariancancer
AT fryatti cisplatincarboplatincrossresistanceinovariancancer
AT wiltshawe cisplatincarboplatincrossresistanceinovariancancer
AT dawsont cisplatincarboplatincrossresistanceinovariancancer
AT robinsonba cisplatincarboplatincrossresistanceinovariancancer
AT calvertah cisplatincarboplatincrossresistanceinovariancancer

Ejemplares similares